Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury

April 13, 2023 updated by: Ekso Bionics
A safety and feasibility study of robotic exoskeleton training in deconditioned patients residing in a healthcare facility.

Study Overview

Status

Completed

Detailed Description

Patients who are hospitalized for several weeks or months are at a higher risk of decline in physical condition and are also at a higher risk of rehospitalization within 30 days of discharge. A program incorporating robotic exoskeleton training may provide sufficient physical support and challenge for patients to maintain a higher level of physical condition than if they did not undergo exoskeleton training. The investigators aim to demonstrate that EksoGT robotic exoskeleton training can be performed safely with patients who have been hospitalized and are at risk of experiencing a further decline in their physical condition.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • Wallingford, Connecticut, United States, 06492
        • Gaylord Specialty Healthcare
    • Illinois
      • Wheaton, Illinois, United States, 60187
        • Marianjoy Rehabilitation Hospital
    • Nebraska
      • Omaha, Nebraska, United States, 68104
        • Quality Living, Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. A diagnosis of "deconditioned", defined as the loss of muscle tone and endurance due to chronic disease, immobility, or loss of function.
  2. Adults 18 years and older (or as specified by state law).
  3. Admitted into a hospital, long-term care facility, skilled nursing facility, or similar.
  4. Sufficient upper extremity strength to use a front wheeled walker by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and flexion/extension 4/5).
  5. Screened and cleared by a physician for full weight-bearing exercise training.
  6. Weigh 220 pounds (100kg) or less.
  7. Between approximately 5'0" and 6'4" tall.
  8. Standing hip width of approximately 18" or less.
  9. Have near normal range of motion in hips, knees and ankles.

Exclusion Criteria:

  1. Currently involved in another intervention study.
  2. Transferred to the intensive care unit or isolation-room stay.
  3. Currently on a ventilator or extracorporeal membrane oxygenation (ECMO) machine.
  4. Currently have a ventricular assist device (VAD) or an automatic implantable cardioverter-defibrillator (AICD).
  5. Advanced heart failure - ejection fraction of < 20%.
  6. Documented cardiovascular risk from exercise.
  7. Resting heart rate <50 bpm or >120 bpm.
  8. Uncontrolled or new (within 24 hours) arrythmias.
  9. Resting blood pressure below 90/70 or above 160/100.
  10. Oxygen saturation (O2 sat) < 90% during rest.
  11. Uncontrolled or severe orthostatic hypotension that limits standing tolerance.
  12. Cardiac ischemia within 24 hours.
  13. Unresolved or new (within 24 hours) deep vein thrombosis.
  14. Concurrent severe neurological pathology/disease or stroke within 72 hours.
  15. Open skin ulcerations on any body surfaces in contact with exoskeleton.
  16. Acute fracture
  17. Osteoporosis
  18. Active heterotrophic ossification (HO) of the lower extremity, hip dysplasia, or hip/knee axis abnormalities.
  19. Current chemotherapy
  20. Inability to speak or understand the English language.
  21. Inability to cooperate in tests/exercises.
  22. Hip flexion contracture greater than ~17°.
  23. Knee flexion contracture greater than 12°.
  24. Unable to achieve neutral ankle dorsiflexion with passive stretch (neutral with max 12° knee flexion).
  25. Cognitive impairments - unable to follow 2 step commands or to communicate pain or to stop session.
  26. Pregnancy
  27. Any reason the physician may deem as harmful to the participant to enroll or continue in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Interventional Group
All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Who Experience an Adverse Event During Time of Treatment
Time Frame: 2 weeks
The primary endpoint is safety defined as the number of participants experiencing an adverse event per overall during the study period.
2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Who Experience an Adverse Event During Time of Treatment That Was Deemed "Definitely Device Related"
Time Frame: 2 weeks
Count of number of participants who experienced any adverse event that was rated as definitely related to treatment with the Ekso device.
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 11, 2017

Primary Completion (Actual)

December 13, 2018

Study Completion (Actual)

December 13, 2018

Study Registration Dates

First Submitted

November 3, 2017

First Submitted That Met QC Criteria

November 22, 2017

First Posted (Actual)

November 28, 2017

Study Record Updates

Last Update Posted (Actual)

April 14, 2023

Last Update Submitted That Met QC Criteria

April 13, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 107159

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Debility Due to Disease

Clinical Trials on EksoGT with SmartAssist software

Subscribe